Indivior plc turned the page on treatment for severe opioid use disorder (OUD), gaining FDA approval of Sublocade (buprenorphine extended-release, previously RBP-6000) subcutaneous injection as the first once-monthly injectable buprenorphine formulation to treat moderate to severe OUD in patients who initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of seven days. Regulated as a schedule III controlled substance, Sublocade is intended to be administered by providers as part of a treatment program that includes counseling and psychosocial support.